JP4679055B2 - ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用 - Google Patents

ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用 Download PDF

Info

Publication number
JP4679055B2
JP4679055B2 JP2003517072A JP2003517072A JP4679055B2 JP 4679055 B2 JP4679055 B2 JP 4679055B2 JP 2003517072 A JP2003517072 A JP 2003517072A JP 2003517072 A JP2003517072 A JP 2003517072A JP 4679055 B2 JP4679055 B2 JP 4679055B2
Authority
JP
Japan
Prior art keywords
dihydromorphine
glucosyl
hydromorphone
dihydroisomorphine
glucuronide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003517072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500357A5 (enExample
JP2005500357A (ja
Inventor
ガオ，フェン
ミオット，ジャハナラ
Original Assignee
ユーロ−セルティーク エス．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーロ−セルティーク エス．エイ． filed Critical ユーロ−セルティーク エス．エイ．
Publication of JP2005500357A publication Critical patent/JP2005500357A/ja
Publication of JP2005500357A5 publication Critical patent/JP2005500357A5/ja
Application granted granted Critical
Publication of JP4679055B2 publication Critical patent/JP4679055B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2003517072A 2001-07-27 2002-07-24 ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用 Expired - Fee Related JP4679055B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30784501P 2001-07-27 2001-07-27
PCT/US2002/023553 WO2003011881A2 (en) 2001-07-27 2002-07-24 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain

Publications (3)

Publication Number Publication Date
JP2005500357A JP2005500357A (ja) 2005-01-06
JP2005500357A5 JP2005500357A5 (enExample) 2006-01-05
JP4679055B2 true JP4679055B2 (ja) 2011-04-27

Family

ID=23191416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003517072A Expired - Fee Related JP4679055B2 (ja) 2001-07-27 2002-07-24 ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用

Country Status (14)

Country Link
US (1) US6740641B2 (enExample)
EP (1) EP1412368B1 (enExample)
JP (1) JP4679055B2 (enExample)
AT (1) ATE371665T1 (enExample)
AU (1) AU2002329634B2 (enExample)
CA (1) CA2455774C (enExample)
CY (1) CY1107813T1 (enExample)
DE (1) DE60222137T2 (enExample)
DK (1) DK1412368T3 (enExample)
ES (1) ES2292806T3 (enExample)
IL (2) IL160085A0 (enExample)
MX (1) MXPA04000825A (enExample)
PT (1) PT1412368E (enExample)
WO (1) WO2003011881A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
AU2003219863C1 (en) * 2002-02-22 2009-03-05 Shire Llc Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
WO2003072735A2 (en) * 2002-02-22 2003-09-04 New River Pharmaceuticals Inc. Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
GB0218811D0 (en) * 2002-08-14 2002-09-18 Cenes Ltd Salts of morphine-6-glucuronide
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
JP4898445B2 (ja) 2003-05-29 2012-03-14 シャイア エルエルシー 乱用抵抗性アンフェタミン化合物類
EA008864B1 (ru) * 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
CN101426481B (zh) * 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
FR2939436B1 (fr) * 2008-12-10 2010-12-17 Sanofi Aventis Synthese de morphine-6-glucuronide ou de l'un de ses derives
EP2552433A4 (en) 2010-03-30 2013-11-06 Algynomics Inc COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
US8716350B2 (en) * 2010-03-30 2014-05-06 Algynomics Inc. Compositions and methods for the treatment of somatosensory disorders
ME02367B (me) 2010-09-21 2016-06-20 Purdue Pharma Lp Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
IN2014DN03009A (enExample) 2011-10-26 2015-05-08 Kempharm Inc
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
TW201434842A (zh) 2012-12-07 2014-09-16 Purdue Pharma Lp 丁基原啡因（ｂｕｐｒｅｎｏｒｐｈｉｎｅ）類似物類
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
EP2931726B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Spirocyclic morphinans and their use
EP2951160B1 (en) 2013-01-31 2019-04-24 Purdue Pharma LP Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3087057A4 (en) 2013-12-26 2017-06-28 Purdue Pharma LP Ring-contracted morphinans and the use thereof
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
CA2950567A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
CA2969221C (en) 2014-12-02 2021-01-12 Travis Mickle Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
ITUB20154996A1 (it) 2015-10-27 2017-04-27 Nobili S P A Attrezzatura per l?erogazione di un liquido di trattamento ad una rispettiva coltura o piantagione agricola.
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
EP4577667A2 (en) * 2022-08-25 2025-07-02 Biosynth GmbH Procedure for production of opioid-antagonist-releasing compounds and their use as a medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3882961T2 (de) 1988-01-12 1993-12-23 Baker Norton Pharma Glucuronsäure-Derivate von Opioid-Antagonisten.
FR2680786B1 (fr) * 1991-09-04 1995-03-10 Irepa Procede de synthese de glucuronides d'epoxy-4,5 morphinanes.
EP0816375A1 (en) * 1995-11-29 1998-01-07 Rolabo Sl Glycoconjugates of opiated substances
GB9711118D0 (en) 1997-05-29 1997-07-23 Rolabo Sl Compound

Also Published As

Publication number Publication date
CA2455774C (en) 2011-06-07
CY1107813T1 (el) 2013-06-19
DE60222137D1 (de) 2007-10-11
US6740641B2 (en) 2004-05-25
IL160085A0 (en) 2004-06-20
MXPA04000825A (es) 2004-05-17
IL160085A (en) 2010-12-30
EP1412368A2 (en) 2004-04-28
ES2292806T3 (es) 2008-03-16
ATE371665T1 (de) 2007-09-15
CA2455774A1 (en) 2003-02-13
WO2003011881A2 (en) 2003-02-13
WO2003011881A3 (en) 2003-10-30
PT1412368E (pt) 2007-11-06
DE60222137T2 (de) 2008-06-05
EP1412368B1 (en) 2007-08-29
US20030050257A1 (en) 2003-03-13
AU2002329634B2 (en) 2009-01-29
JP2005500357A (ja) 2005-01-06
DK1412368T3 (da) 2008-01-02

Similar Documents

Publication Publication Date Title
JP2005500357A (ja) ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用
AU2002329634A1 (en) Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
ES2312584T3 (es) Compuestos de espiropirazol.
ES2323876T3 (es) Derivados de 1-(4-piperidinil)-1,3-dihidro-2h-benzoxazol-2-ona y compuestos relacionados como analogos de la nociceptina y ligandos de orl1 para el tratamiento del dolor.
JP4401076B2 (ja) ベンズイミダゾロン化合物
KR20050115221A (ko) 통증 치료용 4-테트라조릴-4페닐피페리딘 유도체
KR100729242B1 (ko) 노시셉틴 유사체
JP2011021021A (ja) 疼痛を処置または防止するために有用なトリアザスピロ化合物
KR20080110816A (ko) 퓨린 화합물 및 이의 사용 방법
BRPI0619679A2 (pt) compostos 4-oxadiazolil-piperidina e seus usos
WO2004103305A2 (en) Spiropyrazole compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101026

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110111

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110201

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees